Two Sigma Securities, LLC Salarius Pharmaceuticals, Inc. Transaction History

Two Sigma Securities, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.17 - $41.34 $562 - $136,752	-3,308 Reduced 21.35%	12,187 $2,000
Q2 2022 Aug 15, 2022	BUY	$0.16 - $0.42 $489 - $1,285	3,060 Added 24.61%	15,495 $3,000
Q1 2022 May 16, 2022	BUY	$0.34 - $0.54 $4,227 - $6,714	12,435 New	12,435 $5,000
Q3 2021 Nov 15, 2021	SELL	$0.8 - $1.15 $23,746 - $34,135	-29,683 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.02 - $1.52 $30,276 - $45,118	29,683 New	29,683 $31,000
Q4 2019 Feb 14, 2020	SELL	$3.02 - $5.9 $66,041 - $129,021	-21,868 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.28 - $20.25 $115,463 - $442,827	21,868 New	21,868 $119,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.37M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.